首頁 > 市場調查報告書 > 製藥

開發平台分析

升糖素市場規模、佔有率、成長分析（按適應症、給藥途徑、配方、最終用戶和地區）—2025 年至 2032 年產業預測

市場調查報告書

商品編碼

1801972

升糖素市場規模、佔有率、成長分析（按適應症、給藥途徑、配方、最終用戶和地區）—2025 年至 2032 年產業預測

Glucagon Market Size, Share, and Growth Analysis, By Indication (Hypoglycemia, Diabetic Ketoacidosis), By Route of Administration (Intravenous, Subcutaneous), By Formulation, By End-User, By Region - Industry Forecast 2025-2032

出版日期: 2025年08月25日 | 出版商:

SkyQuest | 英文 185 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年全球升糖素市場規模為 6.08 億美元，預計將從 2024 年的 6.4448 億美元成長到 2032 年的 10.272 億美元，預測期內（2025-2032 年）的複合年成長率為 6.0%。

由於糖尿病盛行率上升、緊急醫療治療的普及以及嚴重低血糖管理意識的不斷增強，全球升糖素市場正經歷強勁成長。隨著醫療保健系統優先考慮可靠的治療方案，對有效低血糖治療的需求正在飆升。緊急注射劑和鼻腔內製劑的進步正在改善患者的治療效果並提高市場滲透率。對醫護人員和患者進行低血糖發作緊急應變的教育，進一步刺激了需求。此外，藥物輸送系統技術的不斷創新和政府的優惠醫療政策也在推動市場擴張。然而，治療成本高、低收入地區認知度有限、監管障礙以及對低溫運輸物流的依賴等挑戰，持續影響市場策略與區域發展。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 按部門分類的公司佔有率分析
- 收益同比對比（2022-2024 年）

主要企業簡介

Sun Pharmaceuticals Industries
Zealand Pharma
Biocon
KemPharm
Baxter International
Sandoz
Teva Pharmaceuticals Industries
Reddy's Laboratories
Mylan
Pfizer
Novo Nordisk
Xeris Pharmaceuticals
Eli Lilly and Company

結論和建議

簡介目錄

Product Code: SQMIG35H2367

Global Glucagon Market size was valued at USD 608.0 million in 2023 and is poised to grow from USD 644.48 million in 2024 to USD 1027.2 million by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).

The global glucagon market is witnessing robust growth driven by the escalating prevalence of diabetes, increased adoption of emergency medical treatments, and heightened awareness surrounding severe hypoglycemia management. Demand for effective hypoglycemia interventions is surging as healthcare systems prioritize reliable treatment options. Advancements in emergency injectable solutions and nasal glucagon formulations are improving patient outcomes and enhancing market penetration. Efforts to educate healthcare professionals and patients on the urgency of addressing hypoglycemic episodes are further amplifying demand. Additionally, ongoing innovations in drug delivery systems and favorable government healthcare policies are fostering market expansion. However, challenges such as high treatment costs, insufficient awareness in lower-income regions, regulatory hurdles, and reliance on cold-chain logistics continue to impact market strategies and regional uptake.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glucagon market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glucagon Market Segments Analysis

Global Glucagon Market is segmented by Indication, Route of Administration, Formulation, End-User and region. Based on Indication, the market is segmented into Hypoglycemia, Diabetic Ketoacidosis and Metabolic Disease Trials. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous and Intramuscular. Based on Formulation, the market is segmented into Injectable Kits, Liquid Stable Autoinjectors, Nasal Powder and Liquid Stable Vials. Based on End-User, the market is segmented into Hospitals, Clinic, Drug Stores, Online Pharmacies and Home Care Setting. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Glucagon Market

The rising prevalence of diabetes, particularly type 1 diabetes, worldwide is a significant factor propelling the growth of the glucagon market. Individuals living with insulin-dependent diabetes face the constant risk of severe hypoglycemia, which requires prompt intervention. This urgent healthcare necessity has led to a heightened demand for glucagon treatment options in various settings, including hospitals, clinics, and homecare environments. As the awareness of diabetes management and emergency response continues to expand, the need for effective glucagon solutions becomes more pronounced, further fueling the market's expansion and innovation in treatment methods.

Restraints in the Global Glucagon Market

The advanced glucagon delivery systems, including prefilled autoinjectors and nasal powders, present significant financial challenges due to their high development and production costs. This elevated pricing may hinder their acceptance, particularly in low- and middle-income countries, where affordability is a critical concern. Additionally, these expenses place a burden on healthcare systems and insurance providers, complicating the wider distribution and accessibility of innovative treatment options. As a result, the potential benefits of these modern glucagon formulations may not be realized on a broad scale, limiting the overall impact on patient care and health outcomes.

Market Trends of the Global Glucagon Market

The Global Glucagon market is experiencing notable growth driven by advancements in drug delivery technologies, such as liquid-stable formulations, nasal sprays, and autoinjectors. These innovations enhance the convenience and efficacy of glucagon administration, eliminating the need for reconstitution and improving shelf stability. This ease of use is particularly beneficial during emergencies, as it allows for prompt intervention in cases of severe hypoglycemia. As healthcare providers and patients increasingly demand more user-friendly solutions, the market is poised for expansion, reflecting a broader trend towards patient-centric approaches in diabetes management and emergency care.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies

Global Glucagon Market Size by Indication & CAGR (2025-2032)

Market Overview
Hypoglycemia
Diabetic Ketoacidosis
Metabolic Disease Trials

Global Glucagon Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Intravenous
Subcutaneous
Intramuscular

Global Glucagon Market Size by Formulation & CAGR (2025-2032)

Market Overview
Injectable Kits
Liquid Stable Autoinjectors
Nasal Powder
Liquid Stable Vials

Global Glucagon Market Size by End-User & CAGR (2025-2032)

Market Overview
Hospitals
Clinic
Drug Stores
Online Pharmacies
Home Care Setting

Global Glucagon Market Size & CAGR (2025-2032)

North America (Indication, Route of Administration, Formulation, End-User)
- US
- Canada
Europe (Indication, Route of Administration, Formulation, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Indication, Route of Administration, Formulation, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Indication, Route of Administration, Formulation, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Indication, Route of Administration, Formulation, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Sun Pharmaceuticals Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zealand Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocon
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KemPharm
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceuticals Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Xeris Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments